Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

13,415 total articles

IREN Acquires Awaken to Support Global Brand Growth

IREN Acquires Awaken to Support Global Brand Growth

IREN Limited, a NASDAQ-listed AI Cloud data center and GPU cluster provider, has acquired Awaken, a creative and media agency that has been its external marketing partner. Bringing Awaken's team in-house aims to strengthen IREN's brand awareness and marketing capabilities as it expands into new regions including North America, Europe, and APAC. Thi…

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

NRx Pharmaceuticals reported significant progress in Q1 2026 including anticipated FDA decision on preservative-free ketamine ANDA, initiation of commercial manufacturing at 1 million doses per month, FDA acceptance of NRX-101 IND for adjunct TMS therapy, expansion of interventional psychiatry clinics, and pending acquisition of assets targeting se…

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

Can-Fite BioPharma and Vetbiolix published a peer-reviewed study demonstrating Piclidenoson significantly improves clinical signs of canine osteoarthritis with a favorable safety profile. This validates Piclidenoson’s potential as an oral disease-modifying therapy in a large veterinary market. The drug is under development by Vetbiolix through a li…

INNEOVA Holdings Reports Fiscal Year 2025 Financial Results; Operating Cash Flow Increases 75% as Engineering Transformation Advances

INNEOVA Holdings Reports Fiscal Year 2025 Financial Results; Operating Cash Flow Increases 75% as Engineering Transformation Advances

INNEOVA Holdings Limited reported its fiscal year 2025 financial results, highlighting a 75% increase in operating cash flow to $4.4 million despite a slight revenue decline due to softer international demand. The company successfully integrated the acquired INNEOVA Engineering business and secured significant contracts including a multi-year overh…

Ashland Board appoints Bertrand Loy as new director

Ashland Board appoints Bertrand Loy as new director

Ashland Inc. announced the appointment of Bertrand Loy to its board of directors effective May 15, 2026. Loy brings extensive experience from the technology industry, particularly from his leadership roles at Entegris Inc. His addition supports Ashland's strategic objectives to expand, innovate, and pursue scalable growth globally. The board size w…

Orion Group Holdings Announces Conference Participation

Orion Group Holdings Announces Conference Participation

Orion Group Holdings, a specialty construction company, announced that its management will participate in two major investor conferences in May 2026. The company serves infrastructure, industrial, and building sectors through marine and concrete services across various North American and Caribbean regions.

Quantum Cyber to Exhibit at Special Operations Forces Week 2026

Quantum Cyber to Exhibit at Special Operations Forces Week 2026

Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, announced its participation as an exhibitor at Special Operations Forces Week (SOF Week) 2026 in Tampa, Florida. The company will present its multi-mission autonomous UAV platform designed for surveillance, interdiction, and payload delivery, aligning with the needs of globa…

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Regeneron Pharmaceuticals announces a strategic collaboration with Parabilis Medicines to develop new therapeutic candidates based on Parabilis' Helicon™ peptide platform combined with Regeneron's antibody technology. The deal includes a $125 million investment from Regeneron, potential milestone payments up to $2.2 billion, and aims to create inno…

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

Design Therapeutics announced encouraging clinical and biomarker results from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2, an investigational gene-targeted therapy for Friedreich Ataxia. The drug demonstrated dose-dependent increases in frataxin mRNA and protein levels, along with measurable clinical improvements in neurological function and…

Brady Corporation Reports Record Adjusted EPS in its Fiscal 2026 Third Quarter and Raises its Fiscal 2026 Adjusted EPS Guidance

Brady Corporation Reports Record Adjusted EPS in its Fiscal 2026 Third Quarter and Raises its Fiscal 2026 Adjusted EPS Guidance

Brady Corporation announced strong third quarter fiscal 2026 financial results with a 13.8% sales increase, 23% rise in adjusted diluted EPS to $1.50, and improved full-year adjusted EPS guidance. The company also entered into an agreement to acquire Honeywell's Productivity Solutions and Services business, expected to close in the second half of 2…

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

Perspective Therapeutics, Inc. announced dosing of first patients in new cohorts of two ongoing Phase 1/2a clinical trials involving their radiopharmaceuticals [212Pb]VMT-α-NET for neuroendocrine tumors and [212Pb]PSV359 for solid tumors expressing fibroblast activation protein alpha (FAP-α). These trials aim to optimize dosing regimens and evaluat…

Sachem Capital Corp. and Industrial Realty Group Announce Strategic Combination to Create IRG Realty Trust, a Top-10 Public Industrial REIT

Sachem Capital Corp. and Industrial Realty Group Announce Strategic Combination to Create IRG Realty Trust, a Top-10 Public Industrial REIT

Sachem Capital Corp. and Industrial Realty Group announced a strategic combination where IRG will contribute 98 industrial assets to Sachem, creating IRG Realty Trust (IRGT) with an implied enterprise value of approximately $3.4 billion. The deal transforms Sachem from a subscale mortgage REIT to a top-10 publicly listed industrial REIT that focuse…

Auddia Highlights LT350’s AI Infrastructure Opportunity Using Newly Disclosed Market Pricing Benchmarks

Auddia Highlights LT350’s AI Infrastructure Opportunity Using Newly Disclosed Market Pricing Benchmarks

Auddia Inc. underscores the significant AI infrastructure opportunity for its LT350 subsidiary by referencing SharonAI Holdings' recently disclosed $1.25 billion, 5-year GPU cloud contract, benchmarking potential revenue per GPU and scaling LT350's market potential. The company plans to merge with Thramann Holdings to form McCarthy Finney (NASDAQ: …

EHang Provides Investors Q&A regarding Form 6-K/A

EHang Provides Investors Q&A regarding Form 6-K/A

EHang Holdings Limited issued a Form 6-K/A correcting unaudited interim financial data for 2025 and provided an investor Q&A to address related inquiries. The company reaffirmed its leadership in advanced air mobility technology, highlighting certifications for its pilotless eVTOL aircraft and its plans for expanding autonomous air transport servic…

iQIYI Announces First Quarter 2026 Financial Results

iQIYI Announces First Quarter 2026 Financial Results

iQIYI, Inc., a leading Chinese online entertainment provider, reported its unaudited Q1 2026 financial results with total revenues declining 13% year-over-year to RMB6.23 billion (US$902.5 million). The company saw an operating loss of RMB228.4 million and a net loss attributable to iQIYI of RMB294.6 million, a significant retreat from profitabilit…

VEON Announces Investor Meetings for a Potential Dual Tranche USD Notes Offering and Related Tender Offer for 2027 Notes

VEON Announces Investor Meetings for a Potential Dual Tranche USD Notes Offering and Related Tender Offer for 2027 Notes

VEON Ltd. announced that its subsidiary VEON MidCo B.V. is conducting investor meetings for a potential offering of unsecured US dollar medium term notes in two tranches to extend debt maturity. Concurrently, it launched a tender offer to repurchase outstanding 3.375% Senior Notes due 2027 for up to $750 million, aimed at optimizing capital structu…